Regulatory Mechanisms of Extracellular Matrix Glycosylation in Tissue Homeostasis Maintenance and Remodeling

The extracellular matrix is not a static scaffold simply composed of collagen, elastin, and several adhesion molecules. Its functional state largely depends on the spatial structure, ligand-binding capacity, and local signal distribution shaped by glycosylation. Glycosaminoglycan chains, glycan modifications on proteoglycan core proteins, and glycosylation-dependent matrix assembly processes collectively determine tissue hydration, mechanical buffering, factor storage, cell adhesion, and inflammatory threshold. Research on extracellular matrix glycosylation is, in essence, an effort to understand how tissues use glycan-encoded structural information to maintain homeostasis, respond to stress, and enter repair or pathological remodeling programs.

 

Keywords: extracellular matrix; glycosylation; proteoglycan; glycosaminoglycan; heparan sulfate; hyaluronic acid; tissue homeostasis; matrix remodeling; growth factor storage; inflammatory regulation

 

I. Structural Basis and Research Scope of Extracellular Matrix Glycosylation

1.1 Extracellular matrix glycosylation is not an accessory modification

(1) Glycan chains determine the accessibility and surface properties of matrix macromolecules

Extracellular matrix proteins are often accompanied by different types of glycosylation modifications during secretion, assembly, and maturation. These glycans not only alter protein folding and secretion efficiency, but also determine surface charge, spatial volume, and binding capacity toward ions, cell receptors, and growth factors. Therefore, glycosylation is not a decorative structure added onto matrix proteins, but an important component of their functional conformation.

(2) Glycosylation transforms the matrix from a structural layer into an informational layer

When proteoglycan side-chain length, sulfation pattern, and terminal sugar residue distribution change, the storage and release patterns of TGF-β, FGF, VEGF, Wnt, and chemokines within the matrix also change accordingly. This indicates that extracellular matrix glycosylation not only determines physical scaffold properties, but also determines how local signaling microenvironments are organized.

 

1.2 The research object includes not only glycans themselves, but also their generation and editing processes

(1) Glycan synthesis depends on coordinated assembly by multiple enzymes

Glycosyltransferases, sulfotransferases, epimerases, and glycosidases collectively participate in glycan initiation, elongation, modification, and degradation. Therefore, understanding matrix glycosylation cannot stop at whether a certain glycan exists, but must further analyze its synthetic pathway and editing mechanism.

(2) Glycan degradation also has regulatory significance

Hyaluronidases, heparinase-like active molecules, and heparanase can alter glycan chain length and sulfated fragment distribution, thereby reshaping interstitial diffusion properties, inflammatory cell migration routes, and growth factor availability. Glycan degradation is not passive loss, but an active process of tissue homeostasis remodeling.

 

II. Major Types and Functional Stratification of Extracellular Matrix Glycosylation

2.1 Proteoglycan side chains are the core carriers of matrix glycan information

(1) Heparan sulfate chains are responsible for factor capture and local signal organization

Heparan sulfate chains are widely found on basement membrane and cell-surface proteoglycans, and their sulfation patterns directly affect the local accumulation and receptor presentation efficiency of FGF, VEGF, HGF, Wnt, and other molecules. Thus, heparan sulfate is not merely a negatively charged polysaccharide, but an important molecular template for the spatial organization of growth factors.

(2) Chondroitin sulfate and dermatan sulfate are more closely associated with mechanical buffering and regulation of tissue viscoelasticity

These glycosaminoglycans absorb water through their highly dense negative charge and regulate collagen fiber spacing, thereby maintaining compressive resistance and viscoelastic characteristics in cartilage, vascular walls, and interstitial tissues. Changes in their abundance and conformation often directly reflect whether tissue has entered a fibrotic, degenerative, or repair-remodeling state.

(3) Keratan sulfate-related glycans are more closely associated with ordered arrangement and maintenance of tissue transparency

In highly ordered tissues such as the cornea and cartilage, keratan sulfate-related glycans help regulate fiber arrangement and matrix spacing, thereby maintaining transparency and fine structural stability. Changes in such glycans often indicate disruption of highly tissue-specific homeostasis.

 

2.2 Hyaluronic acid constitutes the non-sulfated matrix backbone

(1) Hyaluronic acid determines interstitial hydration and diffusion environment

Hyaluronic acid is highly hydrophilic and is an important determinant of tissue hydration, cellular migration space, and inflammatory cell infiltration pathways. Its high-molecular-weight form generally supports homeostasis maintenance, whereas low-molecular-weight fragments are more likely to participate in inflammatory activation and damage signal amplification.

(2) Hyaluronic acid does not function in isolation

Hyaluronic acid often forms functional complexes with versican, aggrecan, CD44, and other molecules. Its significance lies in jointly establishing a plastic but controlled interstitial environment. Therefore, changes in hyaluronic acid metabolism often imply that tissue homeostasis is shifting from a buffering state toward a remodeling state.

 

2.3 Glycosylation of matrix proteins themselves determines assembly quality and receptor recognition

(1) N-glycosylation and O-glycosylation affect matrix protein secretion and maturation

The secretion, stability, and glycan processing of multiple matrix proteins and their related receptors are closely linked. If glycosylation is insufficient or glycan patterns are abnormal, protein folding may be hindered, secretion efficiency may decline, or extracellular assembly may become abnormal.

(2) Differences in glycoforms of glycoproteins alter cell–matrix interactions

Under different glycoform conditions, the same type of matrix protein may show marked changes in affinity toward integrins, lectins, and growth factor complexes. This means that the glycosylation state of matrix proteins themselves is also part of the tissue homeostasis regulatory layer.

 

Table 1. Major Types of Extracellular Matrix Glycosylation and Their Functional Positioning

 

Glycosylation Type/Component	Main Carrier	Core Structural Feature	Main Functional Positioning	Relationship to Tissue Homeostasis
Heparan sulfate	Proteoglycan side chains	Highly heterogeneous sulfation patterns	Growth factor storage, receptor presentation, local signal organization	Determines regeneration, angiogenesis, and inflammatory threshold
Chondroitin sulfate	Proteoglycan side chains	Dense negative charge and strong water retention	Mechanical buffering, compressive resistance, maintenance of tissue viscoelasticity	Influences cartilage, vascular wall, and interstitial stability
Dermatan sulfate	Proteoglycan side chains	Closely related to collagen assembly	Regulation of collagen fiber spacing, matrix structural ordering	Influences fibrous tissue maturation and scar remodeling
Keratan sulfate-related glycans	Specific proteoglycans	Highly tissue-specific	Regulation of fiber arrangement and structural transparency	Closely related to the homeostasis of highly ordered tissues
Hyaluronic acid	Non-sulfated glycosaminoglycan	High-molecular-weight linear polysaccharide	Maintenance of hydration, regulation of cell migration space	Determines inflammation, repair, and matrix looseness
N-glycosylation/O-glycosylation	Matrix proteins and receptors	Covalent glycan modification of proteins	Affects secretion, folding, stability, and ligand recognition	Determines the functional output boundary of matrix proteins

 

III. How Extracellular Matrix Glycosylation Maintains Tissue Homeostasis

3.1 Regulation of tissue homeostasis through mechanical properties

(1) Glycan chains determine matrix hydration and local stress dispersion

The osmotic effect generated by the high-density negative charge of glycosaminoglycans enables tissues to maintain appropriate swelling and hydration. This property is especially important for cartilage, skin, vascular adventitia, and organ interstitium, because tissue compressive resistance and buffering capacity depend largely on such glycosylated structures.

(2) Glycosylation changes the assembly quality of collagen networks

Glycans can influence matrix stiffness by regulating collagen fiber spacing, fibril bundling degree, and the local crosslinking environment. Tissues are not more stable simply because they are harder, but rather require a mechanical window appropriate for organ function. Extracellular matrix glycosylation is an important determinant of maintaining this window.

 

3.2 Regulation of homeostatic signaling through ligand storage and release

(1) Matrix glycans are important components of growth factor reservoirs

Many cytokines are not freely diffused in tissue fluid, but are captured by glycans such as heparan sulfate and stored locally in high-density forms. This storage mode means that signals are not uniformly distributed, but organized as spatial gradients, thereby supporting functional compartmentalization in stem cell niches, wound edges, and perivascular regions.

(2) Glycan editing processes can alter factor availability

When heparanase, sulfation-modifying enzymes, or related degradation processes become active, signaling molecules originally restricted in the matrix may be re-released or redistributed, thereby altering cell proliferation, migration, and differentiation behavior. Therefore, glycan changes often precede obvious tissue phenotypic changes.

 

3.3 Regulation of inflammatory threshold through glycans

(1) A high-molecular-weight glycan environment helps restrict excessive inflammatory amplification

Under homeostatic conditions, intact matrix glycans help maintain tissue barriers, limit disordered migration of inflammatory cells, and buffer local oxidative and protease stress. Their essential role is to maintain a tissue state that is responsive but not excessive.

(2) Glycan fragments can be converted into damage signals

Once high-molecular-weight hyaluronic acid or proteoglycan side chains are cleaved into low-molecular-weight fragments, their biological significance may shift from maintaining homeostasis to signaling damage and amplifying inflammation. Thus, the homeostatic role of extracellular matrix glycosylation depends not only on quantity, but also on chain length, conformation, and fragment state.

 

IV. Extracellular Matrix Glycosylation Abnormalities and Tissue Remodeling

4.1 Fibrosis is not simply collagen accumulation, but an overall change in the glycosylation environment

(1) Glycan patterns in fibrotic tissues often undergo systemic reprogramming

Under chronic inflammation and persistent mechanical stress, proteoglycan expression profiles, glycan chain length, and sulfation distribution can all change. Such changes not only accompany collagen deposition, but also alter tissue stiffness, cell migration, and factor retention characteristics.

(2) Abnormal glycans can amplify profibrotic signals such as TGF-β

When the storage and presentation environment related to heparan sulfate changes, profibrotic factors are more easily enriched and persistently activated locally, thereby promoting fibroblast activation and excessive matrix deposition.

 

4.2 In degenerative disease and chronic injury, glycan integrity is an important boundary condition

(1) Cartilage degeneration is often accompanied by proteoglycan loss and decreased water retention

This means that the tissue not only loses elasticity and buffering capacity, but also loses the osmotic environment required to maintain local cellular homeostasis. Glycan depletion is often an important early event in functional degeneration.

(2) Vascular and organ interstitial injury also involves destruction of glycosylation barriers

Once glycan integrity in basement membranes and pericellular matrices declines, inflammatory cells, proteases, and pro-angiogenic signals can more easily enter tissues abnormally, thereby driving chronic remodeling.

 

4.3 Glycosylation remodeling in tumor and regenerative microenvironments has bidirectional significance

(1) The regenerative environment requires moderate glycan remodeling

In the early stage of injury repair, local glycan editing helps release growth factors and promotes cell migration and angiogenesis. Therefore, short-term remodeling has physiological significance.

(2) Persistent abnormal remodeling can be converted into a pathological microenvironment

If glycan degradation, abnormal sulfation, and proteoglycan reorganization persist, tissues may enter a state characterized by enhanced invasion, abnormal angiogenesis, and chronic inflammatory maintenance.

 

V. Key Issues in Research and Translation

5.1 Research cannot focus only on the abundance of a single matrix component

(1) Changes in abundance do not equal changes in function

The same glycosaminoglycan may have completely different functional significance depending on chain length, sulfation position, and its binding protein environment. Therefore, measuring total amount alone is often insufficient to explain changes in tissue homeostasis.

(2) Greater attention should be paid to the relationship between glycan structure and functional output

Integrated analysis of growth factor binding, cell migration, matrix stiffness, and inflammatory readouts can better reflect the true biological consequences of glycosylation changes.

 

5.2 Methodologically, both structural and functional layers should be covered

(1) Structural-layer research should focus on glycan type, length, and sulfation pattern

This includes glycosaminoglycan quantification, enzymatically digested fragment analysis, fluorescently labeled oligosaccharide distribution, and proteoglycan core protein expression.

(2) Functional-layer research should focus on signaling and tissue outcomes

This includes growth factor binding, cell adhesion and migration, barrier integrity, inflammatory factor expression, and tissue mechanical readouts.

 

5.3 Common research indicators

(1) Matrix composition indicators

① Hyaluronic acid content.

② Heparan sulfate content.

③ Chondroitin sulfate/dermatan sulfate-related proteoglycan levels.

④ Proteoglycan core protein expression.

These indicators are used to determine whether the glycan environment of the matrix has changed globally.

(2) Glycan structure indicators

① Glycan chain length distribution.

② Degree of sulfation.

③ Oligosaccharide fragment spectrum after enzymatic digestion.

④ Terminal glycan modification state.

These indicators are used to explain why the same type of glycan can produce different functional outcomes.

(3) Functional output indicators

① Binding or release levels of FGF, TGF-β, VEGF, and other factors.

② Cell migration and adhesion capacity.

③ Tissue water content and mechanical parameters.

④ Expression of inflammatory factors and proteases.

These indicators are used to truly connect glycosylation changes with tissue homeostatic consequences.

 

VI. Commonly Used Products for Related Research

6.1 Matrix Glycan Substrates and Modified Polysaccharides for Extracellular Matrix Glycosylation and Tissue Homeostasis Research

 

Catalog No.	Name	Grade and Purity	Corresponding Research Stage	Applicable Research Direction / Use
H131007	Hyaluronic acid	Moligand™, From Cockscomb	Basic matrix glycan substrate	Used to construct a highly hydrated ECM environment and analyze tissue hydration, cell migration, and the repair microenvironment
H758227	Sodium Heparan Sulfate	≥95%, Potency:20-50 IU/mg	Basic glycan substrate	Suitable for routine heparan sulfate functional studies and protein binding experiments
H758784	Heparan Sulfate	≥95%(HPLC), wt: 2,000-3,000	Chain length-dependent studies	Suitable for analyzing the effects of low-molecular-weight heparan sulfate on diffusion and binding behavior
H758369	2-O-desulfated Heparan Sulfate	≥95%, Potency:<10IU/mg	Site-specific desulfation editing	Suitable for studying the effects of loss of 2-O sulfation on ECM glycan function
O758411	2-O-desulfated Heparan Sulfate（sodium salt）	≥95%, Potency:≤10IU/mg	Site-specific desulfation editing	Suitable for 2-O site functional studies in aqueous systems
H758340	6-O-desulfated Heparan Sulfate	≥95%, Potency:<10IU/mg	Site-specific desulfation editing	Suitable for analyzing the role of 6-O sulfation in ligand recognition and receptor presentation
N758374	N-desulfated Heparan Sulfate（sodium salt）	≥95%, Potency:≤10IU/mg	N-site desulfation editing	Suitable for studying the contribution of N-sulfation to glycan information encoding
N758166	N-Acetyl-2-O-sulfated heparin (Heparin III-A) sodium salt	≥95%, Potency：≤30IU/mg	Modified heparin structural tool	Suitable for functional comparison of structures with specific sulfation/acetylation combinations
N130949	N-Acetyl-de-O-sulfated heparin (Heparin IV-A) sodium salt	Reagent Grade	Modified heparin structural tool	Suitable for structure–function analysis of low-sulfated heparin derivatives
H758419	Heparosan sodium salt	≥95%, Potency:<10IU/mg	Heparin precursor-like material	Suitable for studying differences between low-activity precursor-type glycans and mature highly sulfated glycans
H1455956	Heparosan		Precursor polysaccharide material	Suitable for studying the relationship between heparosan/heparin biosynthetic precursors and subsequent modifications
H283846	HEPARINOID		Heparin-like substitute material	Suitable for simulation and functional substitution studies of heparin-like polysaccharides
H758710	Heparin sodium	≥95%(HPLC), wt: 3,000-5,000	Heparin chain length control	Suitable for comparative studies of highly sulfated chain length versus heparan sulfate
E413286	Enoxaparin sodium	PharmPure™, USP	Low molecular weight heparin control	Suitable as a control for comparing the pharmacological properties of highly sulfated low-molecular-weight heparin with ECM glycan functions
H284086	Enoxaparin sodium（from Hog intestine）	Moligand™	Low molecular weight heparin control	Suitable for control experiments with clearly defined source-specific low-molecular-weight heparin
H283849	Heparin calcium	Mw 15000-19000	Heparin salt-form material	Suitable for comparing functional differences among different salt forms of heparin
H426844	Heparin sodium salt	Moligand™, 2mM in Water	Standard heparin tool molecule	Suitable for routine heparin-binding and competitive experiments
H758151	Heparin sodium salt	≥99%, ≥150(units/mg), from sheep intestinal mucosa	High-purity heparin material	Suitable for structural and activity studies under clearly defined source conditions
H101524	Heparin lithium salt	~200 units/mg	Heparin salt-form material	Suitable for functional comparison under different cation coordination backgrounds
H284091	Heparin sodium	Moligand™, Anti factor Xa titersPotency110~210IU/mg	Low molecular weight heparin control	Suitable for functional comparison of highly sulfated low-molecular-weight heparins
N283851	Nadroparin Calcium	Average molecular weight: 3600-5000	Low molecular weight heparin control	Suitable for structural and activity comparison among different low-molecular-weight heparins

 

6.2 Oligosaccharide Fragments, Disaccharide Standards, and Labeled Probes for Extracellular Matrix Glycosylation and Tissue Homeostasis Research

 

Catalog No.	Name	Grade and Purity	Corresponding Research Stage	Applicable Research Direction / Use
H758741	Heparan Sulfate oilgosaccharide mix	≥95%	Heparan sulfate fragment spectrum study	Suitable for analyzing the overall structural and functional features of mixed heparan sulfate oligosaccharide systems
H758743	Heparan Sulfate DP2	≥95%(HPLC)	Minimal functional fragment study	Suitable for analysis of binding activity and structural boundaries of the shortest-chain fragments
H758746	Heparan Sulfate DP4	≥95%(HPLC)	Short-chain oligosaccharide study	Suitable for local binding and receptor recognition studies
H758748	Heparan Sulfate DP6	≥95%(HPLC)	Short-to-medium oligosaccharide study	Suitable for analyzing changes in factor binding capacity with increasing chain length
H758750	Heparan Sulfate DP8	≥90%	Medium-chain oligosaccharide study	Suitable for growth factor storage and protein binding studies
H758752	Heparan Sulfate DP10	≥90%	Longer oligosaccharide study	Suitable for simulating the function of relatively complete local glycan chain fragments
H758293	Heparan sulfate fraction I	≥95%, Potency:<20IU/mg，wt. approx. 40KD	Fractionated component study	Suitable for structural and activity analysis of high-molecular-weight fractions
H758317	Heparan sulfate fraction III	≥95%, Potency:<40IU/mg，wt. approx. 9KD	Fractionated component study	Suitable for functional comparison of low-molecular-weight fractions
H758662	Heparin sodium DP2	≥95%(HPLC)	Basic heparin fragment study	Suitable for functional analysis of minimal structural units of heparin
H758675	Heparin sodium DP4	≥95%(HPLC)	Short-chain heparin oligosaccharide study	Suitable for chain length-dependent protein binding analysis
H758677	Heparin sodium DP6	≥95%(HPLC)	Short-to-medium-chain heparin oligosaccharide study	Suitable for functional comparison of heparin fragment–protein interactions
H758680	Heparin sodium DP8	≥95%(HPLC)	Medium-chain heparin oligosaccharide study	Suitable for functional studies of longer heparin fragments
H758686	Heparin sodium DP10	≥95%(HPLC)	Longer heparin oligosaccharide study	Suitable for simulating the function of relatively complete highly sulfated fragments
H758655	Heparin sodium oligosaccharide mix	≥95%(HPLC)	Heparin fragment spectrum study	Suitable for overall oligosaccharide distribution and protein binding analysis
H759000	Heparin disaccharide mixture	≥95%(HPLC)	Disaccharide standard system	Suitable for disaccharide composition analysis after heparin/heparan sulfate enzymatic digestion
H759002	Heparin disaccharide I-A sodium salt（α-ΔUA-2S-[1→4]-GlcNAc-6S）	≥95%	Standard disaccharide structural analysis	Suitable for disaccharide-level structural quantification and standard control
H477667	Heparin disaccharide I-S sodium salt(α-ΔUA-2S-[1→4]-GlcNS-6S)	sulfated heparin fragment	Standard disaccharide structural analysis	Suitable for structural identification of highly sulfated fragments
H486656	Heparin disaccharide I-H sodium salt	≥98%	Standard disaccharide structural analysis	Suitable for comparison of disaccharides with different amino-group states
H759004	Heparin disaccharide II-A sodium salt（α-ΔUA-[1→4]-GlcNAc-6S）	≥95%	Standard disaccharide structural analysis	Suitable for structural comparison of different disaccharide subtypes
H759977	Heparin disaccharide II-H sodium salt（α-ΔUA-[1→4]-GlcN-6S）	≥95%	Standard disaccharide structural analysis	Suitable for disaccharide structural spectrum comparison studies
H486655	Heparin disaccharide II-H disodium salt		Standard disaccharide structural analysis	Suitable for structural comparison of disaccharides with different salt forms
H759975	Heparin disaccharide III-A sodium salt（α-ΔUA-2S-[1→4]-GlcNAc）	≥95%	Standard disaccharide structural analysis	Suitable for establishing standards for multiple heparin disaccharide subtypes
H759990	Heparin disaccharide III-H sodium salt（α-ΔUA-2S-[1→4]-GlcN）	≥95%	Standard disaccharide structural analysis	Suitable for structural isomer fragment analysis
H759995	Heparin disaccharide III-S sodium salt（α-ΔUA-2S-[1→4]-GlcNS）	≥95%	Standard disaccharide structural analysis	Suitable for studies of highly sulfated disaccharides
H486657	Heparin disaccharide IV-A sodium salt（α-ΔUA-[1→4]-GlcNAc）	≥95%	Standard disaccharide structural analysis	Suitable for structural comparison of low-modification fragments
H759993	Heparin disaccharide IV-H sodium salt（α-ΔUA-[1→4]-GlcN）	≥95%	Standard disaccharide structural analysis	Suitable for analysis of terminal structural variants
H759999	Heparin disaccharide IV-S sodium salt	≥95%	Standard disaccharide structural analysis	Suitable for establishing disaccharide standard libraries and LC analysis
H760002	Heparin disaccharide mixture fluorescence labeling（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled structural analysis	Suitable for disaccharide quantification and enzymatic digestion analysis on fluorescence detection platforms
H760004	Heparin disaccharide I-A sodium salt fluorescence labeling（α-ΔUA-2S-[1→4]-GlcNAc-6S）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for fluorescence quantification studies of single disaccharide standards
H760018	Heparin disaccharide I-H sodium salt fluorescence labeling（α-ΔUA-2S-[1→4]-GlcN-6S）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for high-sensitivity detection of heparin fragments
H760035	Heparin disaccharide I-S sodium salt fluorescence labeling（α-ΔUA-2S-[1→4]-GlcNS-6S）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for tracking studies of highly sulfated disaccharide fragments
H760009	Heparin disaccharide II-A sodium salt fluorescence labeling（α-ΔUA-[1→4]-GlcNAc-6S）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for control detection of different disaccharide subtypes
H760023	Heparin disaccharide II-H sodium salt fluorescence labeling（α-ΔUA-[1→4]-GlcN-6S）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for structural isomer fragment detection
H760039	Heparin disaccharide II-S sodium salt fluorescence labeling（α-ΔUA-[1→4]-GlcNS-6S）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for high-sensitivity disaccharide spectrum analysis
H760011	Heparin disaccharide III-A sodium salt fluorescence labeling（α-ΔUA-2S-[1→4]-GlcNAc）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for fine disaccharide structural studies
H760027	Heparin disaccharide III-H sodium salt fluorescence labeling（α-ΔUA-2S-[1→4]-GlcN）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for combined disaccharide structural and signaling analysis
H760043	Heparin disaccharide III-S sodium salt fluorescence labeling（α-ΔUA-2S-[1→4]-GlcNS）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for highly sulfated fragment spectrum studies
H760014	Heparin disaccharide IV-A sodium salt fluorescence labeling（α-ΔUA-[1→4]-GlcNAc）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for tracking studies of low-modification fragments
H760032	Heparin disaccharide IV-H sodium salt fluorescence labeling（α-ΔUA-[1→4]-GlcN）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for high-sensitivity detection of disaccharide isomer fragments
H760049	Heparin disaccharide IV-S sodium salt fluorescence labeling（α-ΔUA-[1→4]-GlcNS）（2-Aminobenzamide)	≥95%(HPLC)	Fluorescently labeled disaccharide analysis	Suitable for establishing fluorescent disaccharide standard systems
B758406	Biotin heparan sulfate sodium salt	≥95%	Labeled glycan probe	Suitable for protein binding, pull-down, and solid-phase detection experiments
F758385	Fluorescein heparan sulfate	≥95%	Fluorescent glycan tracer	Suitable for binding kinetics, cellular uptake, and localization studies
F758173	Fluorescein heparin sodium	≥99%	Fluorescent heparin tool	Suitable for heparin binding, cellular uptake, and ligand competition experiments
H464269	Heparin−biotin sodium salt	≥97%	Biotin-labeled heparin tool	Suitable for solid-phase binding experiments and protein pull-down analysis
H758291	Heprin specific protein probe	1 mg/ml	Recognition probe	Suitable for recognition of heparin-like glycans and binding-site detection
H274982	Heparin-Binding Peptide I	≥95%	Heparin recognition tool	Suitable for studying protein–heparin binding sites and binding competition relationships
H276315	Heparin-Binding Peptide II	≥95%	Heparin recognition tool	Suitable for functional studies of heparin recognition sequences
H275182	Heparin-Binding Peptide III	≥95%	Heparin recognition tool	Suitable for structure–function comparison of different heparin-binding peptides

 

6.3 Key Enzymes, Degradation/Editing Tools, and Detection Reagents for Extracellular Matrix Glycosylation and Tissue Homeostasis Research

 

Catalog No.	Name	Grade and Purity	Corresponding Research Stage	Applicable Research Direction / Use
U1445123	UDP-glucose dehydrogenase		UDP-glucuronic acid generation	Suitable for studies on precursor supply for hyaluronic acid, heparan sulfate, and other glycosaminoglycans; an important upstream enzyme linking sugar metabolism with ECM polysaccharide synthesis
U1443170	Uridine-5'-diphosphoglucose pyrophosphorylase		UDP-glucose generation	Suitable for studying UDP-glucose generation in ECM glycan precursor supply pathways; has upstream indicative significance for hyaluronic acid, heparan sulfate, and related glycosaminoglycan precursor metabolism
B755120	Beta-1,4-galactosyltransferase 1	Bioactive,Recombinant,ActiBioPure™,High Performance,EnzymoPure™,His Tag, expressed in Baculovirus-BTI-TN-5B1-4 Cells；>2000 U/mg protein；Protein concentration: See COA	Matrix glycoprotein glycan processing	Suitable for studying how terminal galactosylation and glycan maturation of matrix-related glycoproteins affect secretion, stability, and extracellular assembly
B1438840	Beta-1,4-Galactosyltransferase 1 (Y285L)	Bioactive,Recombinant,ActiBioPure™,High Performance,EnzymoPure™,His Tag, expressed in HEK293；>1000 U/mg protein；Protein concentration: See COA	Matrix glycoprotein glycan processing	Suitable for glycan modification specificity studies and construction of ECM glycoprotein processing models under enzyme engineering conditions
B1507859	Bovin beta-1,4-galactosyltransferase 1	Bioactive,Recombinant,ActiBioPure™,High Performance,EnzymoPure™,His Tag, expressed in Baculovirus-BTI-TN-5B1-4 Cells；>2000 U/mg protein；Protein concentration: See COA	Matrix glycoprotein glycan processing	Suitable for cross-species comparison and establishment of in vitro glycan processing systems
B1443293	Bovin beta-1,4-galactosyltransferase 1 (Y289L)	Bioactive,Recombinant,ActiBioPure™,High Performance,EnzymoPure™,His Tag, expressed in HEK293；>1000 U/mg protein；Protein concentration: See COA	Matrix glycoprotein glycan processing	Suitable for studying glycan processing efficiency and substrate preference in recombinant enzyme engineering systems
M1507860	Mouse Beta-1,4-galactosyltransferase 1 (Y286L)	Bioactive,Recombinant,ActiBioPure™,High Performance,EnzymoPure™,His Tag, >2000 U/mg protein；Protein concentration: See COA；expressed in HEK293	Matrix glycoprotein glycan processing	Suitable for studies on glycan maturation of ECM glycoproteins in mouse-related systems
H1492277	Recombinant Hyaluronidase	ActiBioPure™, Bioactive, Animal Free, High Performance, EnzymoPure™, Recombinant, ≥95%(SDS-PAGE), >60000U/mL, >60000U/mg protein	Hyaluronic acid degradation	Suitable for studying the conversion of hyaluronic acid from a high-molecular-weight homeostatic form to a low-molecular-weight remodeling form
H766309	Hyaluronidase（specificity for hyaluronate sodium）	EnzymoPure™, ≥2000UN/mg，from Streptomyces hyalurolyticus	Hyaluronic acid-specific degradation	Suitable for more specifically analyzing the role of hyaluronic acid in matrix hydration, cell migration, and injury response
H128645	Hyaluronidase from bovine testes(Purified)	EnzymoPure™, ≥3,000 USP/NF units/mg dry weight	Hyaluronic acid degradation	Suitable as a classical hyaluronic acid-degrading tool enzyme for interstitial loosening and ECM remodeling models
H1435491	Heparanase 1, Human		Heparan sulfate chain degradation	Suitable for studying the key editing processes involved in heparan sulfate-mediated storage signal release, inflammatory amplification, angiogenesis, and tissue remodeling
EJ1513769	Human Heparanase(HPA) ELISA Kit	BioReagent	Heparanase level detection	Suitable for evaluating changes in heparanase in human samples and its relationship with tissue remodeling
EJ1512952	Mouse Heparanase (HPSE) ELISA Kit	BioReagent	Heparanase level detection	Suitable for mouse ECM remodeling and inflammation model studies
EJ1512953	Mouse Heparan Sulfate Proteoglycan (HSPG) ELISA Kit	BioReagent	Overall HSPG detection	Suitable for evaluating changes in heparan sulfate proteoglycan levels in mouse tissues
EJ1512954	Mouse Heparan Sulfate Proteoglycan 2 (HSPG2) ELISA Kit	BioReagent	HSPG2/Perlecan detection	Suitable for basement membrane and proteoglycan homeostasis studies
H766335	Heparinase I	Bioactive, ActiBioPure™, EnzymoPure™, High Performance, ≥90%(SDS-PAGE), ≥6000 U/mL	Heparin/heparan sulfate enzymatic digestion	Suitable for analyzing highly sulfated glycan fragment structures and functional differences before and after enzymatic digestion
H766338	Heparinase II	Bioactive,ActiBioPure™,High Performance,EnzymoPure™,≥90%(SDS-PAGE),≥2400 U/mL for 25U and 100U; ≥240 U/mL for 10U	Heparin/heparan sulfate enzymatic digestion	Suitable for complementary glycan cleavage analysis under different substrate preferences
H766341	Heparinase III	Bioactive,ActiBioPure™,High Performance,EnzymoPure™,≥90%(SDS-PAGE),≥3000 U/mL for 50U; ≥300 U/mL for 5U and 10U	Heparan sulfate-specific enzymatic digestion	Suitable for structural editing and fragment studies more specifically targeting heparan sulfate chains
H766347	Heparinase I and III blend	EnzymoPure™, ≥200(U/mg)，from Flavobacterium heparinum	Combined enzymatic digestion tool	Suitable for obtaining more complete heparan sulfate fragment profiles
H766343	Heparinase I, II and III blend	EnzymoPure™, ≥200(U/mg)，from Flavobacterium heparinum	Comprehensive enzymatic digestion tool	Suitable for overall structural analysis of heparan sulfate/heparin in complex samples

 

6.4 Small Molecules for Glycosylation Processing and Sulfation Regulation in Extracellular Matrix Glycosylation and Tissue Homeostasis Research

 

Catalog No.	Name	Grade and Purity	Corresponding Research Stage	Applicable Research Direction / Use
C1499888	Castanospermine	Moligand™, 10 mM in DMSO	N-glycan processing inhibition	Suitable for inhibiting glucosidase-related glycoprotein processing and studying structural and secretion changes after impaired ECM glycoprotein maturation
C130954	Castanospermine	≥98%	N-glycan processing inhibition	Suitable for studying the effects of blocked N-glycan processing of matrix proteins on tissue homeostasis
S130953	Swainsonine	≥98%	Complex-type glycan processing inhibition	Suitable for analyzing the effects of ECM glycoprotein glycoform shifts after inhibition of mannosidase-related processing steps
K1498846	Kifunensine	Moligand™, 10 mM in DMSO	High-mannose retention intervention	Suitable for studying the effects of high-mannose retention on matrix glycoprotein maturation and extracellular assembly
K274698	Kifunensine	≥98%	High-mannose retention intervention	Suitable for mechanistic studies of glycan processing stages
T101151	Tunicamycin	≥98%	N-glycosylation initiation inhibition	Suitable for studying folding, secretion, and assembly abnormalities of ECM secreted proteins under N-glycosylation-deficient conditions
O288697	OGT 2115	≥97%(HPLC)	Heparanase inhibition	Suitable for inhibiting heparan sulfate degradation and analyzing the effects of matrix glycan integrity on tissue homeostasis

 

Extracellular matrix glycosylation is not a marginal issue in matrix research, but a fundamental regulatory layer for tissue homeostasis maintenance, stress responses, and pathological remodeling. What truly determines matrix function is not the isolated presence of a single protein or a single glycosaminoglycan, but the coordinated relationship among glycan type, chain length, sulfation pattern, degradation state, and the local signaling network. Therefore, research on extracellular matrix glycosylation should always proceed along the continuous logic of structure, signaling, and tissue outcome, so that one can more accurately understand how tissues remain stable and why they enter states of dysregulated repair and pathological remodeling.

 

For more related articles, please see below:

[1] Glycosylation in Biopharmaceuticals